Page 167 - CW E-Magazine (17-12-2024)

News from Abroad

devices approved and certified for over “With the purchase of GEM, Medifill, a complementary customer base across
80 internal indications. The acquisi- and our previous acquisitions in this the architectural and infrastructure
tion establishes a European headquar- space, H.B. Fuller has now built a Medi- markets.
ters for H.B. Fuller’s Medical Adhe- cal Adhesive Technologies business
sive Technologies (MAT) business and founded on our expertise in cyanoacry- The reorganisation includes the
expands the company’s medical adhe- late chemistry, and we have extended sale of the Flooring business as well
sive offerings. our penetration into a global footprint.” as combining the company’s Insulated
Glass, Woodworking, and Composite
These acquisitions build upon H.B. When combined, the two compa- segments, currently part of Engineer-
Fuller’s previous investments in the nies are expected to generate 2024 ing Adhesives, with its Roofing and
tissue adhesives market – including the net revenue and adjusted EBITDA of Building Envelope and Infrastructure
acquisition of Cyberbond in 2016, Tissue €23-mn and €11.5-mn, respectively. The (BE&I) segments to form a newly
Seal in 2021, and Adhezion Biomedical two companies will operate within named Global Business Unit (GBU):
in 2023 – significantly expanding the H.B. Fuller’s Hygiene, Health & Building Adhesive Solutions (BAS),
company’s global Medical Adhesive Consumable (HHC) Adhesives Global effective with the start of H.B. Fuller’s
Technologies (MAT) business and Business Unit (GBU). 2025 fiscal year. BAS replaces H.B.
geographic footprint. Fuller’s existing Construction Adhe-
Divestiture of flooring business sives GBU.
“Tissue adhesives designed for In another development, H.B. Fuller
internal use offer innovative alternatives Company announced that it will H.B. Fuller also announced that it
to traditional sutures, staples and reorganise the building and construction has sold its Flooring business to Pacific
embolising agents,” said H.B. Fuller’s segments of its portfolio to create a Avenue Capital Partners, a leading
President and CEO Ms. Celeste Mastin. faster growing solutions business with private equity firm based in Los Angeles.

NOVEL DELIVERY SYSTEM
Givaudan completes capacity expansion for

encapsulation technologies in Mexico

Swiss maker of flavours, fragrances
and active cosmetic ingredients,
Givaudan, has announced the inaugura-
tion of its newly expanded production
facility at the Pedro Escobedo site in
Mexico. “This expansion is a pivotal
step in our fragrance and beauty strategy.
It has successfully doubled our pro-
duction capacity, which now represents
40% of Givaudan’s global capacity in
this sector. This strategic growth not
only reflects our engagement to meet
the increasing demands of our custo- the investments in Singapore in 2022, this processes,” added Mr. Andrew Sted-
mers but also positions us as a leader in next step in Mexico is another mile- man, Head of Operations, Fragrance &
this market,” commented Mr. Maurizio stone in our development of encapsu- Beauty, Givaudan.
Volpi, President Fragrance & Beauty, lation technologies. Furthermore, Pedro-
Givaudan. Escobedo’s facility and equipment Encapsulation technologies form
have been designed to reinforce our one of the pillars of the Givaudan busi-
“This continues our investment in dedication to operational excellence ness. “All these investments not only
delivery systems capacity in Pedro and ensure that we maintain the highest support our current endeavours but also
Escobedo, aligned with meeting our quality and Good Manufacturing Prac- lay the groundwork for future innova-
global growth expectations. Following tice (GMP) standards, in our production tions,” the company informed.

Chemical Weekly December 17, 2024 167

Contents Index to Advertisers Index to Products Advertised